Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal

SIMPLE SUMMARY: Skin melanoma is fully curable by surgery if diagnosed at an early stage. Targeted drugs against BRAF(V600) and MEK1/2 were the first therapeutic breakthrough for patients with advanced melanoma. However, acquired drug resistance resulting in disease relapse interrupts the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartman, Mariusz L., Koziej, Paulina, Kluszczyńska, Katarzyna, Czyz, Małgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571954/
https://www.ncbi.nlm.nih.gov/pubmed/37835493
http://dx.doi.org/10.3390/cancers15194799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571954/
https://www.ncbi.nlm.nih.gov/pubmed/37835493
http://dx.doi.org/10.3390/cancers15194799

Ejemplares similares